Interferon (IFN)-α is an effective and safe recombinant human protein with broad clinical appeal. While recombinant IFN-α has great therapeutic value, its utility for biodefense is hindered by its short *in vivo* half-life and costly production. Here we describe the use of Ad5-mIFN-α (DEF201) to address these limitations as a prophylactic countermeasure in two murine viral challenge models, Punta Toro virus (PTV; *Bunyaviridae*, *Phlebovirus*) and SARS coronavirus (CoV). Significant protection (*p*  \< 0.001) against PTV and SARS-CoV infections was observed in mice from a single dose of DEF201 administered 1 day to 3 weeks prior to challenge. DEF201 was delivered intranasally to stimulate mucosal immunity at the probable site of infection and bypass any preexisting immunity. Intramuscular inoculation with DEF201 rapidly increased (∼3 h) IFN-α concentrations in unchallenged mice and persisted for extended periods of time. In contrast, a control Ad5 construct elicited only small amounts of IFN-α that were short-lived. Studies investigating the kinetics of mucosal and systemic IFN-α levels following intranasal administration of DEF201 are underway. Effective medical countermeasures that are highly stable, easily administered, and elicit long lasting protective immunity are much needed. The DEF201 technology has the potential to address all of these issues and serves as a broad-spectrum approach to enhance host defense against a number of viral pathogens.

**Acknowledgement:** Supported by N01-AI-30063 (awarded to Southern Research Institute), Virology Branch, NIAID, NIH, and DRDC CRA.
